Recombinant Human PLAU/uPA Protein (active form)
Beta LifeScience
SKU/CAT #: BLK-01495P-100UG

Human PLAU (activated by trypsin) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human PLAU/uPA Protein (active form)
Beta LifeScience
SKU/CAT #: BLK-01495P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human PLAU/uPA Protein (active form) is expressed from HEK293 with His tag at the C-Terminus.It contains Ser21-Leu431, which consists of two chains: Long chain A (Ser21-Phe177) and chain B (Ile179-Leu 431). The long chain A is further cleaved to yield a short chain A (Lys156-Phe 177) and N-Terminus fragment (Ser21-Lys155). |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P00749 |
Target Symbol | PLAU/uPA |
Synonyms | PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Ser21-Leu431 |
Mol. Weight | The protein has a predicted MW of 17.9 kDa (long chain A), 29.2 kDa (chain B) and 15.3 kDa (N-terminal fragment). The protein migrates to 30-38 kDa (chain B) and 17 kDa (N-terminal fragment) based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 1% HCOOH, 1mM DTT (pH 3.0). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. |